This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, Select Medical Holdings, LHC, Eurofins Scientific and DaVita
5 Healthcare Stocks to Keep the Winning Streak Alive in 2020
by Sapna Bagaria
Increasing incidence of chronic diseases, aging U.S. population, innovation and consolidation will drive the healthcare industry's growth in 2020.
Amedisys (AMED) Benefits From Home Health and Personal Care
by Zacks Equity Research
Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.
Teladoc Adds to its Services With Tailored Nutrition Plans
by Zacks Equity Research
Teladoc (TDOC) enhances its service portfolio with the addition of personalized diet programs.
Amedisys (AMED) Up 24.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Amedisys, PC Connection, NRG and Target
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, PC Connection, NRG and Target
Amedisys (AMED) to Broaden Hospice Base With Asana Purchase
by Zacks Equity Research
Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.
4 Momentum Picks Screened on Driehaus Strategy
by Nitish Marwah
Richard Herman Driehaus used the "buy high and sell higher" rule to create an investment approach, which appeals to those having a high level of risk appetite.
The Zacks Analyst Blog Highlights: Amedisys, DaVita, Tenet and Hanger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amedisys, DaVita, Tenet and Hanger
4 Healthcare Stocks to Gain From Stellar Q3 Earnings
by Manaswita Ghosh Dutta
Prominent activities in the healthcare sector are pushing the sector ahead this quarter.
Top Ranked Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd
Here's Why Momentum Investors Will Love Amedisys (AMED)
by Zacks Equity Research
Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amedisys (AMED) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amedisys, Six Flags Entertainment, Target, Walmart and Disney highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Amedisys, Six Flags Entertainment, Target, Walmart and Disney highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Amedisys (AMED)
by Madeleine Johnson
This home healthcare stock has generated big growth in 2019.
Amedisys Partners With nVoq to Improve Clinician Experience
by Zacks Equity Research
Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.
3 Reasons Growth Investors Will Love Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Amedisys (AMED) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Amedisys (AMED).
5 Stocks That Stand Out on Attractive Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Amedisys (AMED) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Zacks Analyst Blog Highlights: NRG, AquaVenture, Addus, Amedisys and Bluerock Residential
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NRG, AquaVenture, Addus, Amedisys and Bluerock Residential
Amedisys (AMED) Q3 Earnings Beat Estimates, Revenues Meet
by Zacks Equity Research
Amedisys (AMED) continues to witness solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
Is Amedisys (AMED) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
5 Top Stocks to Gain From Fed's Stable Monetary Stance
by Nalak Das
Fed was compelled to reduce it in three consecutive and equal tranches of 25 basis points to sustain the expansion of the U.S. economy.
New Strong Buy Stocks for October 31st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday